Hospitals, diagnostics likely to stay India’s steadiest earnings story in AMJ26

While large swathes of corporate India head into the June quarter bracing for another muted showing, hospitals and diagnostic chains look set to remain the exception. The sector has delivered double-digit revenue growth for several quarters running, and early indicators suggest the April-June 2026 period will extend that run, even as questions grow louder about how long a business built on capacity expansion and rising realisations can keep outrunning valuation concerns.

For hospital operators, the core growth engine has not changed: more occupied beds, higher revenue per occupied bed (ARPOB), and a steadily improving payer mix as insurance penetration deepens across metros and, increasingly, tier-2 cities. Max Healthcare has maintained occupancy in the mid-70 percent range, with ARPOB comfortably above other listed peers, while Fortis has held occupancy around 70 percent even as it has kept adding operational beds, a combination that has pushed its ARPOB and occupied-bed metrics up substantially over the last three years. Apollo Hospitals continues to lean on both its mature hospital base and an aggressive bed-addition program, with roughly half of a planned 1,500 new beds expected to come on stream this fiscal year, and its digital health arm targeted to reach cash EBITDA breakeven in the very quarter now closing. Narayana Hrudayalaya and Global Health have both been cited among preferred picks by brokerages heading into results, largely on the strength of steady patient volumes and disciplined cost control despite continued capacity additions.

The complication for the quarter is that much of this growth is coming from operators who are simultaneously in expansion mode, and freshly commissioned beds tend to be a drag on margins before they mature. Yatharth Hospitals, KIMS and smaller regional chains are ploughing large sums into new capacity even as they report healthy topline growth, meaning consolidated margin expansion this quarter will likely come more from the mature, high-occupancy hospitals subsidizing the newer, still-ramping ones rather than from broad-based operating leverage. Investors will be watching whether newer units are converging towards target occupancy quickly enough to justify the capital being deployed, since the sector’s entire investment case rests on the assumption that today’s capex converts into tomorrow’s ARPOB.

Diagnostics chains face a different, somewhat less flattering, dynamic. Pricing power remains largely absent in a fragmented, competitive testing market, so growth continues to be driven almost entirely by volumes rather than realisations. Dr Lal PathLabs, which reports on July 24, has guided for FY27 revenue growth of 13-15 percent with EBITDA margins steady in the 27-28 percent range, aided by an expanding non-Covid, wellness-led testing mix and deeper push into smaller towns rather than urban market share battles. Metropolis Healthcare closed the prior quarter with growth near 23 per cent year-on-year, and Vijaya Diagnostics and Thyrocare have both posted record or near-record revenues, suggesting the sector’s shift toward preventive health screening and chronic-disease monitoring is proving durable rather than a pandemic-era blip. The onset of the monsoon toward the tail end of the quarter typically nudges up testing volumes for seasonal and vector-borne illnesses, a modest but reliable tailwind that diagnostics chains have historically benefited from in the June-to-September window.

What ties both halves of the sector together this quarter is valuation. Diagnostics stocks are trading at roughly 22 times estimated FY27 earnings, at a premium to domestic pharmaceutical companies despite comparable growth and return-on-capital profiles, yet remain at a discount to hospital valuations. That combination leaves little room for disappointment: any sign that volume growth is decelerating, that new hospital beds are ramping up more slowly than guided, or that competitive intensity from new entrants and IPO-bound regional chains is compressing pricing further could trigger a sharper re-rating than the underlying business fundamentals alone would suggest.

Results season effectively opens with Max Healthcare, which closed its trading window from July 1 ahead of its Q1FY27 announcement, followed closely by Apollo Hospitals, Fortis and Dr Lal PathLabs later in the month.

Barring a meaningful surprise, the broad expectation is for hospitals to post high-teens revenue growth and diagnostics to deliver low-double-digit growth, both with modest sequential margin gains.

The bigger test for the quarter may not be the headline numbers at all, but whether management commentary offers enough reassurance that the sector’s premium valuations are still underpinned by a genuinely lengthening runway for capacity and demand, rather than simply extrapolating the last several quarters.
MB Bureau